Business
Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that Health~Holland has awarded another grant of approximately $375,000 USD to Leiden University Medical Center (LUMC) and, through a three-party Consortium Agreement, Acurx Pharmaceuticals. The grant will fund this innovative research project entitled: POLSTOP4MDRO – Assessing conservat
About this update from Acurx Pharmaceuticals, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"The objective of this new phase of collaboration with Leiden University Medical Center (LUMC) is to further advance the recently completed and published pioneering research to determine whether the modes of DNA polymerase pol IIIC (PolC) action and resistance are conserved across important species of Gram-positive multidrug resistant organisms","length":345,"tagName":"p"}]},{"val":[{"type":"text","content":"The previous LUMC-Acurx Health~Holland project successfully elucidated the structure of PolC from E. faecium, a critical Gram-positive human pathogen, in complex with two Acurx pol IIIC inhibitors. These data, using both Acrux's Phase 3-ready ibezapolstat for treatment of C. difficile infection and an advanced preclinical pol IIIC inhibitor from the ongoing discovery program, defined for the first time the structural biology of inhibition at the enzyme target using cryo-electron microscopy","length":498,"tagName":"p"}]},{"val":[{"type":"text","content":"This new grant will enable extending mechanistic research into pol IIIC inhibition to accelerate the development of novel new agents that are systemically active against a range of Gram-positive pathogens resistant to currently available antibiotics","length":249,"tagName":"p"}]},{"val":[{"type":"text","content":"This new research aims to generate the first-ever 3D structure of Pol C from methicillin-resistant Staphylococcus aureus (MRSA) in complex with an Acurx inhibitor to advance discovery of new compounds to treat this high-priority clinical pathogen","length":246,"tagName":"p"}]},{"val":[{"type":"text","content":"Additionally, Acurx intends to leverage its preclinical development program for treatment of inhalational anthrax caused by B. anthracis, a Bioterrorism Category A Threat-Level pathogen","length":185,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1523,"olType":false},{"type":"text","content":"STATEN ISLAND, N.Y., Nov. 18, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that Health~Holland has awarded another grant of approximately $375,000 USD to Leiden University Medical Cent...